Source: Medscape, May 2025
Welcome back, everybody. My name is Teresa Amaral, and it’s really a pleasure to have you back for this Medscape melanoma series. We are going to continue with our second part on what’s next in terms of immunotherapy in the adjuvant setting for patients diagnosed with melanoma.
In the first episode, we discussed the current status of adjuvant therapy reimbursement and utilization — who are the patients that are candidates to receive adjuvant therapy but not neoadjuvant therapy, why we have these therapies approved, and what was the benefit of these therapies. We mentioned that the benefit was in terms of relapse-free survival and distant metastasis-free survival.